Materialise Reconfirms Full-Year Revenue Guidance Amid Growth in Medical and Series Manufacturing
Materialise (MTLS) has reconfirmed its full-year 2026 revenue guidance of EUR 273 million to EUR 283 million following a strong third quarter. The company is seeing significant momentum in its medical division, driven by the demand for personalized healthcare solutions and 3D-printed surgical guides. Additionally, its manufacturing segment is successfully pivoting from prototyping toward high-value series production, particularly within the aerospace, semiconductor, and defense sectors. The software division has also reached a key milestone, completing its transition to a recurring revenue model, which now accounts for 84% of total software revenue. Supported by a net cash reserve of EUR 82.5 million, Materialise is directing research capital toward high-margin healthcare and specialized industrial applications to ensure long-term profitable growth.